87219-22-5

Basic information

• Product Name: (2-OXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID
• Synonyms: 2-Oxo-1-imidazolidineacetic acid;2-(2-oxoiMidazolidin-1-yl)acetic acid;(2-oxo-imidazolidin-l-yl)-acetic acid;2-(2-Oxoimidazolidin-1-yl)
• CAS NO: 87219-22-5
• Molecular Formula: C₅H₈N₂O₃
• Molecular Weight: 144.13
• Mol File: 87219-22-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 487.1 °C at 760 mmHg
• Flash Point: 248.4 °C
• Appearance: /
• Density: 1.379
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.41±0.10(Predicted)
• CAS DataBase Reference: (2-OXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2-OXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID(87219-22-5)
• EPA Substance Registry System: (2-OXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID(87219-22-5)

Safety Data

• Hazardous Substances Data: 87219-22-5(Hazardous Substances Data)

Usage

General Description

"(2-OXO-IMIDAZOLIDIN-1-YL)-ACETIC ACID" is a chemical compound with the molecular formula C6H9N2O3. It belongs to the class of imidazolidines, which are organic compounds containing a five-membered ring with three carbon atoms, one nitrogen atom, and one oxygen atom. The compound is a derivative of imidazolidine-2,4-dione and acetic acid, and it is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical compounds. Its structure and properties make it a versatile and important component in the synthesis of biologically active molecules. Additionally, it has potential applications in organic synthesis and medicinal chemistry due to its ability to participate in a variety of chemical reactions.

Upstream product

• 3699-54-5 2-oxo-imidazolidine-1-ethanol 
• 87219-28-1 N-(2-chloroethylcarbamoyl)glycine t-butyl ester 
• 84047-96-1 N-(2-chloroethylcarbamoyl)-glycine methyl ester 
• 87219-19-0 N-(2-chloroethylcarbamoyl)glycine amide 
• 87219-18-9 N-(2-chloroethylcarbamoyl)glycine 

Relevant articles and documents

PARG INHIBITORY COMPOUNDS

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).